Cemiplimab – Uses, Dosage, Side Effects, Interaction Cemiplimab is a programmed death receptor-1 blocking antibody used to treat cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer. Cemiplimab is a fully human monoclonal antibody that works against programmed death receptor-1 (PD-1), which is a negative regulator of T-cell function. By blocking PD-1, cemiplimab works to enhance T cell-mediated antitumor responses. Cemiplimab is a monoclonal antibody medication for the treatment of squamous cell skin cancer. Cemiplimab belongs to a class of drugs that binds to the programmed death receptor-1 (PD-1), blocking the PD-1/PD-L1 pathway. Cemiplimab was first approved by the FDA on September 28, 2018, as the first FDA-approved treatment for advanced cutaneous squamous cell carcinoma (CSCC). It was later approved to be used in basal cell carcinoma and non-small non-small cell lung cancer.[rx] Cemiplimab was also approved by the European Commission on June 28, 2019.[rx] In October 2022, the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended cemiplimab be granted marketing authorization for the treatment of cervical cancer.[rx] Mechanism of action T cells mediate antitumor activity following activation by antigen receptor signaling and CD28 costimulatory signaling.[rx,rx] T cell proliferation and activation are regulated by a number of T cell immune regulatory checkpoints, including programmed death-1 (PD-1).[rx] PD-1 is an inhibitory co-receptor that is predominantly expressed on the surface of T cells to block T cell activation.[rx,rx,rx] Its ligands, PD-L1, and PD-L2, bind to PD-1 to activate downstream signaling cascades that ultimately result in the inhibition of T cell function such as T cell proliferation, cytokine production, and cytotoxicity.[rx,rx] PD-1 receptor signaling pathway serves to maintain tolerance and regulate any ineffective or harmful immune responses; however, PD-1 signaling can also attenuate immune responses in cases where such protection is needed, such as autoimmune disorders and malignancy.[rx] PD-L1 and PD-L2 are expressed on antigen-presenting cells (APCs) as well as on some types of tumor cells 2,8 as part of an adaptive immune response by tumors.[rx,rx] PD-1 is also upregulated in some cancers, impeding T cell-mediated antitumor activity.6 Cemiplimab is a human PD-1-blocking antibody that binds to PD-1 and blocks its interaction with its ligands. By disinhibiting PD-1-mediated suppression of T cell activity, cemiplimab works to potentiate T cell cytotoxicity against tumors.[rx] Indications Locally advanced or metastatic cutaneous squamous cell carcinoma (mCSCC) in patients who are not candidates for curative surgery or curative radiation. Locally advanced basal cell carcinoma (laBCC) in previously treated patients with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate. Metastatic basal cell carcinoma (mBCC) in patients who were previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for mBCC may be contingent upon verification and description of clinical benefit.[rx,rx] Locally advanced non-small cell lung cancer (NSCLC) in combination with platinum‐based chemotherapy for the first‐line treatment of adults with no EGFR, ALK, or ROS1 aberrations, who are not candidates for surgical resection or definitive chemoradiation. It is also indicated to treat metastatic NSCLC in combination with platinum‐based chemotherapy as first-line treatment in adults.[rx] Locally advanced or metastatic NSCLC as monotherapy for the first-line treatment of adults whose tumors have high PD-L1 expression [Tumor Proportion Score (TPS) ≥ 50%] as determined by an FDA-approved test, with no EGFR, ALK or ROS1 aberrations. Patients with locally advanced NSCLC must not be candidates for surgical resection or definitive chemoradiation.[rx] Locally Advanced Basal Cell Carcinoma Locally Advanced Cutaneous Squamous Cell Carcinoma Locally Advanced Non-Small Cell Lung Cancer Metastatic Non-Small Cell Lung Cancer Metastatic cutaneous squamous cell carcinoma Metastatic Basal cell carcinoma Use in Cancer Cemiplimab-rwlc is approved to treat: Basal cell carcinoma (a type of skin cancer). It is used in patients whose cancer cannot be removed by surgery or has spread after treatment with hedgehog pathway inhibitor therapy or if hedgehog pathway inhibitor therapy cannot be used. Cutaneous squamous cell carcinoma (a type of skin cancer) has spread or cannot be treated with surgery or radiation therapy. Non-small cell lung cancer. It is used in adults whose cancer has not spread outside the chest and cannot be treated with surgery or chemotherapy and radiation therapy or has spread to other parts of the body. It is used: Alone is the first treatment when cancer has the PD-L1 protein but does not have a mutation in the EGFR, ALK, or ROS1 gene. Platinum chemotherapy is the first treatment when cancer does not have a mutation in the EGFR, ALK, or ROS1 gene. The use for metastatic BCC is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that cemiplimab-rwlc provides a clinical benefit in these patients. Cemiplimab-rwlc is also being studied in the treatment of other types of cancer. Contraindications myasthenia gravis, a skeletal muscle disorder a type of inflammation of the lung called interstitial pneumonitis inflammation of the large intestine liver inflammation resulting from an abnormal immune response kidney inflammation pregnancy a patient who is producing milk and breastfeeding Dosage Strengths: rwlc 350 mg/7 mL Squamous Cell Carcinoma 350 mg IV over 30 minutes every 3 weeks until disease progression or unacceptable toxicity Basal Cell Carcinoma 350 mg IV over 30 minutes every 3 weeks until disease progression or unacceptable toxicity For locally advanced basal cell carcinoma (laBCC) previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate For metastatic BCC (mBCC) previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate Dose Adjustments No dose reduction for this drug is recommended: In general, withhold therapy for severe (Grade 3) immune-mediated adverse reactions. Permanently discontinue therapy for life-threatening (Grade 4) or recurrent severe (Grade 3) immune-mediated reactions that require systemic immunosuppressives, or inability to reduce corticosteroid to 10 mg or less prednisone equivalent per day within 12 weeks of initiation. PNEUMONITIS: Grade 2: Withhold therapy; resume if resolved to Grade 1 or less after corticosteroid taper; permanently discontinue if no complete or partial resolution within 12 weeks of initiating steroids or inability to reduce prednisone to less than 10 mg per day (or equivalent) within 12 weeks of initiation. Grade 3 or 4: Permanently discontinue therapy. COLITIS: Grade 2 or 3: Withhold therapy; resume if resolved to Grade 1 or less after corticosteroid taper; permanently discontinue if no complete or partial resolution within 12 weeks of initiating steroids or inability to reduce prednisone to less than 10 mg per day (or equivalent) within 12 weeks of initiation Grade 4: Permanently discontinue therapy. HEPATITIS (WITH NO TUMOR INVOLVEMENT OF THE LIVER): If AST or ALT increases to more than 3 and up to 8 times the upper limit of normal (ULN) OR total bilirubin increases more than 1.5 and up to 3 x ULN: Withhold therapy; resume if resolved to Grade 1 or less after corticosteroid taper; permanently discontinue if no complete or partial resolution within 12 weeks of initiating steroids or inability to reduce prednisone to less than 10 mg per day (or equivalent) within 12 weeks of initiation. If AST or ALT increases to more than 8 x ULN OR total bilirubin increases to more than 3 x ULN: Permanently discontinue therapy. HEPATITIS (WITH TUMOR INVOLVEMENT OF THE LIVER): Baseline AST or ALT is more than 1 and up to 3 x ULN and increases to more than 5 and up to 10 x ULN OR baseline AST or ALT is more than 3 and up to 5 x ULN and increases to more than 8 and up to 10 times ULN: Withhold therapy; resume if resolved to Grade 1 or less after corticosteroid taper; permanently discontinue if no complete or partial resolution within 12 weeks of initiating steroids or inability to reduce prednisone to less than 10 mg per day (or equivalent) within 12 weeks of initiation. AST or ALT increases to more than 10 x ULN OR total bilirubin increases to more than 3 x ULN: Permanently discontinue therapy. ENDOCRINOPATHIES: Grade 3 or 4: Withhold until clinically stable or permanently discontinue depending on severity. NEPHRITIS WITH RENAL DYSFUNCTION: Grade 2 or 3 increased blood creatinine: Withhold therapy; resume if resolved to Grade 1 or less after corticosteroid taper; permanently discontinue if no complete or partial resolution within 12 weeks of initiating steroids or inability to reduce prednisone to less than 10 mg per day (or equivalent) within 12 weeks of initiation. Grade 4 increased blood creatinine: Permanently discontinue therapy. EXFOLIATIVE DERMATOLOGIC CONDITIONS: Suspected SJS, TEN, or DRESS: Withhold therapy; resume if resolved to Grade 1 or less after corticosteroid taper; permanently discontinue if no complete or partial resolution within 12 weeks of initiating steroids or inability to reduce prednisone to less than 10 mg per day (or equivalent) within 12 weeks of initiation. Confirmed SJS, TEN, or DRESS: Permanently discontinue therapy. MYOCARDITIS: Grade 2, 3, or 4: Permanently discontinue therapy. NEUROLOGICAL TOXICITIES: Grade 2: Withhold therapy; resume if resolved to Grade 1 or less after corticosteroid taper; permanently discontinue if no complete or partial resolution within 12 weeks of initiating steroids or inability to reduce prednisone to less than 10 mg per day (or equivalent) within 12 weeks of initiation. Grade 3 or 4: Permanently discontinue therapy. INFUSION-RELATED REACTIONS: Grade 1 or 2: Interrupt or slow the rate of infusion. Grade 3 or 4: Permanently discontinue therapy. Side Effects The Most Common constipation cough; irregular heartbeat; chest pain; or shortness of breath diarrhea; stools that are black, tarry, sticky, or have blood or mucus; or abdominal pain or tenderness yellow eyes or skin; severe nausea or vomiting; dark urine; loss of appetite; unusual bleeding or bruising; or pain or discomfort in right upper stomach area rash; blistering skin; itching; swollen lymph nodes; or painful sores or ulcers in mouth or nose, throat, or genital area decreased urine amount; swelling in your ankles; blood in urine; loss of appetite headache, feeling more hungry or thirsty than usual; increased sweating; extreme tiredness; frequent urination; nausea; vomiting; or weight changes double vision, blurry vision, eye sensitivity to light, eye pain, or changes in vision feeling cold; deepening of voice or hoarseness; hair loss; irritability; dizziness or fainting; fast heartbeat; forgetfulness; or changes in sexual desire confusion, sleepiness, memory problems, changes in mood or behavior, stiff neck, balance problems, or tingling or numbness of arms or legs muscle pain or weakness or muscle cramps More Common new or worsening cough, shortness of breath; chest pain, fast or irregular heartbeats; swollen glands; a seizure; severe headache, confusion, hallucinations, eye pain or redness, vision problems (your eyes may be more sensitive to light); severe muscle pain or weakness, neck stiffness; severe stomach pain, nausea, vomiting, diarrhea, bloody or tarry stools; unusual bruising; transplant rejection–mouth sores, stomach pain, feeling sick or uneasy, rash, pain or swelling near your transplanted organ; kidney problems–swelling in your ankles, blood in your urine, little or no urination; liver problems–right-sided upper stomach pain, loss of appetite, drowsiness, easy bruising or bleeding, dark urine, jaundice (yellowing of the skin or eyes); signs of a hormonal disorder–frequent or unusual headaches, dizziness, feeling very tired, mood or behavior changes, hoarse or deepened voice, increased hunger or thirst, increased urination, constipation, hair loss, sweating, feeling cold, weight gain, or weight loss. tiredness; muscle or bone pain; rash, itching; or nausea, diarrhea. Rare slow or fast heartbeat sneezing sore throat stiff neck or back thickening of bronchial secretions trouble breathing unusual bleeding or bruising unusual tiredness or weakness Blistering, peeling, or loosening of the skin difficulty in moving joint or muscle pain muscle aches, cramps, or stiffness red skin lesions, often with a purple center red, irritated eyes sores, ulcers, or white spots in the mouth or on the lips swollen glands swollen joints Drug Interaction DRUG INTERACTION Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Cemiplimab. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Cemiplimab. Aducanumab The risk or severity of adverse effects can be increased when Aducanumab is combined with Cemiplimab. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cemiplimab. Alirocumab The risk or severity of adverse effects can be increased when Alirocumab is combined with Cemiplimab. Amivantamab The risk or severity of adverse effects can be increased when Cemiplimab is combined with Amivantamab. Anifrolumab The risk or severity of adverse effects can be increased when Anifrolumab is combined with Cemiplimab. Ansuvimab The risk or severity of adverse effects can be increased when Cemiplimab is combined with Ansuvimab. Anthrax immune The risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Cemiplimab. Antilymphocyte The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Cemiplimab. Antithymocyte The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cemiplimab. Articaine The risk or severity of methemoglobinemia can be increased when Cemiplimab is combined with Articaine. Asfotase alfa The risk or severity of adverse effects can be increased when Asfotase alfa is combined with Cemiplimab. Atezolizumab The risk or severity of adverse effects can be increased when Atezolizumab is combined with Cemiplimab. Atoltivimab The risk or severity of adverse effects can be increased when Cemiplimab is combined with Atoltivimab. Avelumab The risk or severity of adverse effects can be increased when Avelumab is combined with Cemiplimab. Bamlanivimab The risk or severity of adverse effects can be increased when Cemiplimab is combined with Bamlanivimab. Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Cemiplimab. Bebtelovimab The risk or severity of adverse effects can be increased when Cemiplimab is combined with Bebtelovimab. Belantamab mafodotin The risk or severity of adverse effects can be increased when Cemiplimab is combined with Belantamab mafodotin. Belimumab The risk or severity of adverse effects can be increased when Belimumab is combined with Cemiplimab. Benralizumab The risk or severity of adverse effects can be increased when Benralizumab is combined with Cemiplimab. Benzocaine The risk or severity of methemoglobinemia can be increased when Cemiplimab is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Cemiplimab is combined with Benzyl alcohol. Besilesomab The risk or severity of adverse effects can be increased when Besilesomab is combined with Cemiplimab. Bevacizumab The risk or severity of adverse effects can be increased when Bevacizumab is combined with Cemiplimab. Bezlotoxumab The risk or severity of adverse effects can be increased when Bezlotoxumab is combined with Cemiplimab. Bimekizumab The risk or severity of adverse effects can be increased when Bimekizumab is combined with Cemiplimab. Blinatumomab The risk or severity of adverse effects can be increased when Blinatumomab is combined with Cemiplimab. Brentuximab vedotin The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Cemiplimab. Brodalumab The risk or severity of adverse effects can be increased when Brodalumab is combined with Cemiplimab. Brolucizumab The risk or severity of adverse effects can be increased when Cemiplimab is combined with Brolucizumab. Bupivacaine The risk or severity of methemoglobinemia can be increased when Cemiplimab is combined with Bupivacaine. Burosumab The risk or severity of adverse effects can be increased when Burosumab is combined with Cemiplimab. Butacaine The risk or severity of methemoglobinemia can be increased when Cemiplimab is combined with Butacaine. Butamben The risk or severity of methemoglobinemia can be increased when Cemiplimab is combined with Butamben. Canakinumab The risk or severity of adverse effects can be increased when Canakinumab is combined with Cemiplimab. Caplacizumab The risk or severity of adverse effects can be increased when Caplacizumab is combined with Cemiplimab. Capromab pendetide The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Cemiplimab. Capsaicin The risk or severity of methemoglobinemia can be increased when Cemiplimab is combined with Capsaicin. Casirivimab The risk or severity of adverse effects can be increased when Cemiplimab is combined with Casirivimab. Catumaxomab The risk or severity of adverse effects can be increased when Catumaxomab is combined with Cemiplimab. Certolizumab pegol The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Cemiplimab. Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Cemiplimab. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Cemiplimab is combined with Chloroprocaine. Cilgavimab The risk or severity of adverse effects can be increased when Cemiplimab is combined with Cilgavimab. Cinchocaine The risk or severity of methemoglobinemia can be increased when Cemiplimab is combined with Cinchocaine. Cocaine The risk or severity of methemoglobinemia can be increased when Cemiplimab is combined with Cocaine. Conjugated estrogens Conjugated estrogens may increase the thrombogenic activities of Cemiplimab. Daratumumab The risk or severity of adverse effects can be increased when Daratumumab is combined with Cemiplimab. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Cemiplimab. Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Cemiplimab. Dienestrol Dienestrol may increase the thrombogenic activities of Cemiplimab. Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of Cemiplimab. Digoxin Immune The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Cemiplimab. Dinutuximab The risk or severity of adverse effects can be increased when Dinutuximab is combined with Cemiplimab. Diphenhydramine The risk or severity of methemoglobinemia can be increased when Cemiplimab is combined with Diphenhydramine. Dostarlimab The risk or severity of adverse effects can be increased when Cemiplimab is combined with Dostarlimab. Dulaglutide The risk or severity of adverse effects can be increased when Dulaglutide is combined with Cemiplimab. Dupilumab The risk or severity of adverse effects can be increased when Dupilumab is combined with Cemiplimab. Durvalumab The risk or severity of adverse effects can be increased when Durvalumab is combined with Cemiplimab. Dyclonine The risk or severity of methemoglobinemia can be increased when Cemiplimab is combined with Dyclonine. Ebola Zaire vaccine The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Cemiplimab. Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Cemiplimab. Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Cemiplimab. Eflapegrastim The risk or severity of adverse effects can be increased when Cemiplimab is combined with Eflapegrastim. Eftrenonacog alfa The risk or severity of adverse effects can be increased when Eftrenonacog alfa is combined with Cemiplimab. Elotuzumab The risk or severity of adverse effects can be increased when Elotuzumab is combined with Cemiplimab. Emapalumab The risk or severity of adverse effects can be increased when Cemiplimab is combined with Emapalumab. Emicizumab The risk or severity of adverse effects can be increased when Emicizumab is combined with Cemiplimab. Eptinezumab The risk or severity of adverse effects can be increased when Eptinezumab is combined with Cemiplimab. Erenumab The risk or severity of adverse effects can be increased when Erenumab is combined with Cemiplimab. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Cemiplimab. Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Cemiplimab. Estetrol Estetrol may increase the thrombogenic activities of Cemiplimab. Estradiol Estradiol may increase the thrombogenic activities of Cemiplimab. Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Cemiplimab. Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Cemiplimab. Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of Cemiplimab. Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Cemiplimab. Estriol Estriol may increase the thrombogenic activities of Cemiplimab. Estrone Estrone may increase the thrombogenic activities of Cemiplimab. Estrone sulfate Estrone sulfate may increase the thrombogenic activities of Cemiplimab. Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Cemiplimab. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Cemiplimab is combined with Ethyl chloride. Etidocaine The risk or severity of methemoglobinemia can be increased when Cemiplimab is combined with Etidocaine. Evolocumab The risk or severity of adverse effects can be increased when Evolocumab is combined with Cemiplimab. Fanolesomab The risk or severity of adverse effects can be increased when Fanolesomab is combined with Cemiplimab. Fremanezumab The risk or severity of adverse effects can be increased when Fremanezumab is combined with Cemiplimab. Galcanezumab The risk or severity of adverse effects can be increased when Galcanezumab is combined with Cemiplimab. Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cemiplimab. Golimumab The risk or severity of adverse effects can be increased when Golimumab is combined with Cemiplimab. Guselkumab The risk or severity of adverse effects can be increased when Guselkumab is combined with Cemiplimab. Hepatitis B immune The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Cemiplimab. Human cytomegalovirus The risk or severity of adverse effects can be increased when Human cytomegalovirus immune globulin is combined with Cemiplimab. immunoglobulin G The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Cemiplimab. immune globulin The risk or severity of adverse effects can be increased when Human Rho(D) immune globulin is combined with Cemiplimab. Human varicella The risk or severity of adverse effects can be increased when Human varicella-zoster immune globulin is combined with Cemiplimab. Ibalizumab The risk or severity of adverse effects can be increased when Ibalizumab is combined with Cemiplimab. Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cemiplimab. Idarucizumab The risk or severity of adverse effects can be increased when Idarucizumab is combined with Cemiplimab. Imdevimab The risk or severity of adverse effects can be increased when Cemiplimab is combined with Imdevimab. Imlifidase The therapeutic efficacy of Cemiplimab can be decreased when used in combination with Imlifidase. Inebilizumab The risk or severity of adverse effects can be increased when Inebilizumab is combined with Cemiplimab. Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Cemiplimab. Inotuzumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Cemiplimab. Ipilimumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Cemiplimab. Isatuximab The risk or severity of adverse effects can be increased when Cemiplimab is combined with Isatuximab. Ixekizumab The risk or severity of adverse effects can be increased when Ixekizumab is combined with Cemiplimab. Lanadelumab The risk or severity of adverse effects can be increased when Lanadelumab is combined with Cemiplimab. Levobupivacaine The risk or severity of methemoglobinemia can be increased when Cemiplimab is combined with Levobupivacaine. Lidocaine The risk or severity of methemoglobinemia can be increased when Cemiplimab is combined with Lidocaine. Loncastuximab The risk or severity of adverse effects can be increased when Cemiplimab is combined with Loncastuximab tesirine. Maftivimab The risk or severity of adverse effects can be increased when Cemiplimab is combined with Maftivimab. Margetuximab The risk or severity of adverse effects can be increased when Cemiplimab is combined with Margetuximab. Meloxicam The risk or severity of methemoglobinemia can be increased when Cemiplimab is combined with Meloxicam. Mepivacaine The risk or severity of methemoglobinemia can be increased when Cemiplimab is combined with Mepivacaine. Mepolizumab The risk or severity of adverse effects can be increased when Mepolizumab is combined with Cemiplimab. Mestranol Mestranol may increase the thrombogenic activities of Cemiplimab. Methoxy polyethylene The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Cemiplimab. Mirvetuximab Soravtansine The risk or severity of adverse effects can be increased when Mirvetuximab Soravtansine is combined with Cemiplimab. Mogamulizumab The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Cemiplimab. Mosunetuzumab The risk or severity of adverse effects can be increased when Cemiplimab is combined with Mosunetuzumab. Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Cemiplimab. Natalizumab The risk or severity of adverse effects can be increased when Natalizumab is combined with Cemiplimab. Necitumumab The risk or severity of adverse effects can be increased when Necitumumab is combined with Cemiplimab. Nivolumab The risk or severity of adverse effects can be increased when Nivolumab is combined with Cemiplimab. Obiltoxaximab The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Cemiplimab. Obinutuzumab The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Cemiplimab. Ocrelizumab The risk or severity of adverse effects can be increased when Ocrelizumab is combined with Cemiplimab. Odesivimab The risk or severity of adverse effects can be increased when Cemiplimab is combined with Odesivimab. Ofatumumab The risk or severity of adverse effects can be increased when Ofatumumab is combined with Cemiplimab. Olaratumab The risk or severity of adverse effects can be increased when Olaratumab is combined with Cemiplimab. Omalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Cemiplimab. Oxetacaine The risk or severity of methemoglobinemia can be increased when Cemiplimab is combined with Oxetacaine. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Cemiplimab is combined with Oxybuprocaine. Palivizumab The risk or severity of adverse effects can be increased when Palivizumab is combined with Cemiplimab. Panitumumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Cemiplimab. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Cemiplimab. Pembrolizumab The risk or severity of adverse effects can be increased when Pembrolizumab is combined with Cemiplimab. Pertuzumab The risk or severity of adverse effects can be increased when Pertuzumab is combined with Cemiplimab. Phenol The risk or severity of methemoglobinemia can be increased when Cemiplimab is combined with Phenol. Polatuzumab vedotin The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Cemiplimab. Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of Cemiplimab. Pramocaine The risk or severity of methemoglobinemia can be increased when Cemiplimab is combined with Pramocaine. Prilocaine The risk or severity of methemoglobinemia can be increased when Cemiplimab is combined with Prilocaine. Procaine The risk or severity of methemoglobinemia can be increased when Cemiplimab is combined with Procaine. Proparacaine The risk or severity of methemoglobinemia can be increased when Cemiplimab is combined with Proparacaine. Propoxycaine The risk or severity of methemoglobinemia can be increased when Cemiplimab is combined with Propoxycaine. Quinestrol Quinestrol may increase the thrombogenic activities of Cemiplimab. Ramucirumab The risk or severity of adverse effects can be increased when Ramucirumab is combined with Cemiplimab. Ranibizumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Cemiplimab. Ravulizumab The risk or severity of adverse effects can be increased when Ravulizumab is combined with Cemiplimab. Raxibacumab The risk or severity of adverse effects can be increased when Raxibacumab is combined with Cemiplimab. Reslizumab The risk or severity of adverse effects can be increased when Reslizumab is combined with Cemiplimab. Risankizumab The risk or severity of adverse effects can be increased when Cemiplimab is combined with Risankizumab. Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Cemiplimab. Romosozumab The risk or severity of adverse effects can be increased when Romosozumab is combined with Cemiplimab. Ropivacaine The risk or severity of methemoglobinemia can be increased when Cemiplimab is combined with Ropivacaine. Sacituzumab The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Cemiplimab. Sarilumab The risk or severity of adverse effects can be increased when Sarilumab is combined with Cemiplimab. Secukinumab The risk or severity of adverse effects can be increased when Secukinumab is combined with Cemiplimab. Siltuximab The risk or severity of adverse effects can be increased when Siltuximab is combined with Cemiplimab. Sotrovimab The risk or severity of adverse effects can be increased when Cemiplimab is combined with Sotrovimab. Spesolimab The risk or severity of adverse effects can be increased when Cemiplimab is combined with Spesolimab. Sulesomab The risk or severity of adverse effects can be increased when Sulesomab is combined with Cemiplimab. Sutimlimab The risk or severity of adverse effects can be increased when Cemiplimab is combined with Sutimlimab. S Estrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Cemiplimab. Synthetic Conjugated Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Cemiplimab. Tafasitamab The risk or severity of adverse effects can be increased when Cemiplimab is combined with Tafasitamab. Tetanus immune The risk or severity of adverse effects can be increased when Tetanus immune globulin, human is combined with Cemiplimab. Tetracaine The risk or severity of methemoglobinemia can be increased when Cemiplimab is combined with Tetracaine. Tezepelumab The risk or severity of adverse effects can be increased when Cemiplimab is combined with Tezepelumab. Tibolone Tibolone may increase the thrombogenic activities of Cemiplimab. Tildrakizumab The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Cemiplimab. Tisotumab vedotin The risk or severity of adverse effects can be increased when Cemiplimab is combined with Tisotumab vedotin. Tixagevimab The risk or severity of adverse effects can be increased when Cemiplimab is combined with Tixagevimab. Tocilizumab The risk or severity of adverse effects can be increased when Tocilizumab is combined with Cemiplimab. Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Cemiplimab. Tralokinumab The risk or severity of adverse effects can be increased when Tralokinumab is combined with Cemiplimab. Trastuzumab The risk or severity of adverse effects can be increased when Trastuzumab is combined with Cemiplimab. Trastuzumab The risk or severity of adverse effects can be increased when Cemiplimab is combined with Trastuzumab deruxtecan. Trastuzumab The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Cemiplimab. Tremelimumab The risk or severity of adverse effects can be increased when Tremelimumab is combined with Cemiplimab. Ustekinumab The risk or severity of adverse effects can be increased when Ustekinumab is combined with Cemiplimab. Vedolizumab The risk or severity of adverse effects can be increased when Vedolizumab is combined with Cemiplimab. Pregnancy and Lactation US FDA pregnancy category Not Assigned Pregnancy Based on its mechanism of action, this drug can cause fetal harm when administered to a pregnant woman. Animal studies have demonstrated that inhibition of the PD1/PD-L1 pathway can lead to an increased risk of immune-mediated rejection of the developing fetus resulting in fetal death. Human IgG4 immunoglobulins (IgG4) are known to cross the placenta; therefore, this drug has the potential to be transmitted from the mother to the developing fetus. Lactation Because of the potential for serious adverse reactions in breastfed children, women should not breastfeed during therapy and for at least 4 months after the last dose. Because this drug is a large protein molecule, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant’s GI tract. The manufacturer recommends that breastfeeding be discontinued during therapy and for 4 months after. How should this medicine be used? Cemiplimab-rwlc injection comes as a solution (liquid) to inject intravenously (into a vein) over 30 minutes by a doctor or nurse in a medical facility or infusion center. It is usually given every 3 weeks. Your doctor may need to slow down your infusion or interrupt or stop your treatment if you experience certain side effects. Tell your doctor immediately if you experience any of the following symptoms during or after your infusion: chills or shaking fever, itching, rash, feeling faint, flushing, nausea, back or neck pain, shortness of breath, dizziness, wheezing, or face swelling. Your doctor may delay, or stop your treatment with cemiplimab-rwlc injection depending on your response to the medication and any side effects that you experience. Talk to your doctor about how you are feeling during and after your treatment. Your doctor or pharmacist will give you the manufacturer’s patient information sheet (Medication Guide) when you begin treatment with cemiplimab-rwic injection each time you receive a dose. Read the information carefully and ask your doctor or pharmacist if you have any questions. You can also visit the Food and Drug Administration (FDA) website (http://www.fda.gov/Drugs/DrugSafety/ucm085729.htm) or the manufacturer’s website to obtain the Medication Guide. What special precautions should I follow? Before receiving a cemiplimab-rwlc injection, tell your doctor and pharmacist if you are allergic to cemiplimab-rwlc injection, any other medications, or any of the ingredients in cemiplimab-rwlc injection. Ask your pharmacist or check the Medication Guide for a list of the ingredients. tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Your doctor may need to change the doses of your medications or monitor you carefully for side effects. tell your doctor if you have received or plan to receive a stem cell transplant that uses donor stem cells (allogeneic) or has ever had an organ transplant. Also, tell your doctor if you have or have ever had diabetes, Crohn’s disease (a condition in which the body attacks the lining of the digestive tract, causing pain, diarrhea, weight loss, and fever), ulcerative colitis (a condition which causes swelling and sores in the lining of the colon [large intestine] and rectum), lupus (a disease in which the body attacks many of its own organs), a nervous system disease such as myasthenia gravis (a disorder of the nervous system that causes muscle weakness), a lung disease or breathing problems, or thyroid, liver or kidney disease. tell your doctor if you are pregnant or plan to become pregnant. You should not become pregnant while you are receiving the cemiplimab-rwlc injection. You will need to have a pregnancy test before you begin receiving this medication. Use effective birth control during your treatment with cemiplimab-rwlc injection and for 4 months after your final dose. If you become pregnant while receiving a cemiplimab-rwlc injection, call your doctor. The cemiplimab-rwlc injection may harm the fetus. tell your doctor if you are breastfeeding. Your doctor will tell you not to breastfeed during your treatment with cemiplimab-rwlc injection and for 4 months after your final dose. References https://pubchem.ncbi.nlm.nih.gov/substance/381118800 https://en.wikipedia.org/wiki/Cemiplimab https://go.drugbank.com/drugs/DB14707 https://medlineplus.gov/druginfo/meds/a618054.html https://www.cancer.gov/about-cancer/treatment/drugs/cemiplimab-rwlc https://www.drugs.com/mtm/cemiplimab.html Show More